Catalyst Pharmaceuticals Ownership
| CPRX Stock | USD 22.55 1.97 9.57% |
Shares in Circulation | First Issued 2004-03-31 | Previous Quarter 124.7 M | Current Value 125.4 M | Avarage Shares Outstanding 59.2 M | Quarterly Volatility 43.1 M |
Catalyst |
Catalyst Stock Ownership Analysis
About 84.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 5.54. The company had not issued any dividends in recent years. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. For more info on Catalyst Pharmaceuticals please contact Richard MBA at 305 420 3200 or go to https://www.catalystpharma.com.Besides selling stocks to institutional investors, Catalyst Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Catalyst Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Catalyst Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Catalyst Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Catalyst Pharmaceuticals Insider Trades History
About 7.0% of Catalyst Pharmaceuticals are currently held by insiders. Unlike Catalyst Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Catalyst Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Catalyst Pharmaceuticals' insider trades
Catalyst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Catalyst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Catalyst Pharmaceuticals backward and forwards among themselves. Catalyst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Catalyst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royce & Associates, Lp | 2024-12-31 | 1.9 M | Bank Of America Corp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Boston Partners Global Investors, Inc | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.2 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.1 M | Kennedy Capital Management Inc | 2024-09-30 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 913 K | Blackrock Inc | 2024-12-31 | 19.4 M | Vanguard Group Inc | 2024-12-31 | 8.4 M |
Catalyst Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Catalyst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Catalyst Pharmaceuticals Outstanding Bonds
Catalyst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Catalyst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Catalyst bonds can be classified according to their maturity, which is the date when Catalyst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Catalyst Pharmaceuticals Corporate Filings
10K | 26th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify | |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.